| Bid | 9.54 |
| Market Cap | 597.02M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -7.94 |
| PE Ratio (ttm) | -1.2 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 9.58 |
| Volume | 186,147 |
| Avg. Volume (20D) | 797,077 |
| Open | 9.81 |
| Previous Close | 9.38 |
| Day's Range | 9.50 - 10.07 |
| 52-Week Range | 8.97 - 30.96 |
| Beta | undefined |
About IMNM
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 a...
Analyst Forecast
According to 5 analyst ratings, the average rating for IMNM stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 213.64% from the latest price.
Next Earnings Release
Analysts project revenue of $3.07M, reflecting a -19.76% YoY shrinking and earnings per share of -0.72, making a 380.00% increase YoY.
1 month ago · businesswire.com
Immunome to Present at the Piper Sandler 36th Annual Healthcare ConferenceBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome'...
2 months ago · businesswire.com
Immunome to Present at Guggenheim's Inaugural Healthcare Innovation ConferenceBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg...
